236 related articles for article (PubMed ID: 30176355)
1. Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: What impact on intestinal colonisation resistance?
Woerther PL; Lepeule R; Burdet C; Decousser JW; Ruppé É; Barbier F
Int J Antimicrob Agents; 2018 Dec; 52(6):762-770. PubMed ID: 30176355
[TBL] [Abstract][Full Text] [Related]
2. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
D'Angelo RG; Johnson JK; Bork JT; Heil EL
Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J;
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145
[TBL] [Abstract][Full Text] [Related]
6. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
Harris PN; Tambyah PA; Paterson DL
Lancet Infect Dis; 2015 Apr; 15(4):475-85. PubMed ID: 25716293
[TBL] [Abstract][Full Text] [Related]
7. Which proportion of extended-spectrum beta-lactamase producing strains could be treated by non-carbapenem beta-lactams?
Canoui E; Tankovic J; Bige N; Alves M; Offenstadt G
Med Mal Infect; 2014 May; 44(5):235-7. PubMed ID: 24780641
[No Abstract] [Full Text] [Related]
8. Extended-spectrum beta-lactamases: implications for the clinical laboratory and therapy.
Harada S; Ishii Y; Yamaguchi K
Korean J Lab Med; 2008 Dec; 28(6):401-12. PubMed ID: 19127103
[TBL] [Abstract][Full Text] [Related]
9. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
[TBL] [Abstract][Full Text] [Related]
10. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.
Watkins RR; Deresinski S
Expert Rev Anti Infect Ther; 2017 Oct; 15(10):893-895. PubMed ID: 28914107
[No Abstract] [Full Text] [Related]
11. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
Tamma PD; Rodriguez-Bano J
Clin Infect Dis; 2017 Apr; 64(7):972-980. PubMed ID: 28362938
[TBL] [Abstract][Full Text] [Related]
12. The times they are a-changin': carbapenems for extended-spectrum-β-lactamase-producing bacteria.
Rodríguez-Baño J
Antimicrob Agents Chemother; 2015 Sep; 59(9):5095-6. PubMed ID: 26100709
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Asakura T; Ikeda M; Nakamura A; Kodera S
Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
[TBL] [Abstract][Full Text] [Related]
14. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study.
Harris PNA; Pezzani MD; Gutiérrez-Gutiérrez B; Viale P; Hsueh PR; Ruiz-Garbajosa P; Venditti M; Tumbarello M; Navarro-Francisco C; Calbo E; Akova M; Giamarellou H; Oliver A; Almirante B; Gasch O; Martínez-Martínez L; Schwaber MJ; Daikos G; Pitout J; Peña C; Hernández-Torres A; Doi Y; Pérez F; Tuon FF; Tacconelli E; Carmeli Y; Bonomo RA; Pascual Á; Paterson DL; Rodríguez-Baño J;
Int J Antimicrob Agents; 2017 Nov; 50(5):664-672. PubMed ID: 28782704
[TBL] [Abstract][Full Text] [Related]
15. Breakpoints for extended-spectrum beta-lactamase-producing Enterobacteriacae: pharmacokinetic/pharmacodynamic considerations.
MacGowan A
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():166-8. PubMed ID: 18154541
[TBL] [Abstract][Full Text] [Related]
16. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
[TBL] [Abstract][Full Text] [Related]
17. A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae.
Gutiérrez-Gutiérrez B; Pérez-Galera S; Salamanca E; de Cueto M; Calbo E; Almirante B; Viale P; Oliver A; Pintado V; Gasch O; Martínez-Martínez L; Pitout J; Akova M; Peña C; Molina J; Hernández A; Venditti M; Prim N; Origüen J; Bou G; Tacconelli E; Tumbarello M; Hamprecht A; Giamarellou H; Almela M; Pérez F; Schwaber MJ; Bermejo J; Lowman W; Hsueh PR; Mora-Rillo M; Natera C; Souli M; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J
Antimicrob Agents Chemother; 2016 Jul; 60(7):4159-69. PubMed ID: 27139473
[TBL] [Abstract][Full Text] [Related]
18. The prevalence and drug resistance pattern of extended spectrum β-lactamases (ESBLs) producing Enterobacteriaceae in Africa.
Saravanan M; Ramachandran B; Barabadi H
Microb Pathog; 2018 Jan; 114():180-192. PubMed ID: 29196174
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Collins VL; Marchaim D; Pogue JM; Moshos J; Bheemreddy S; Sunkara B; Shallal A; Chugh N; Eiseler S; Bhargava P; Blunden C; Lephart PR; Memon BI; Hayakawa K; Abreu-Lanfranco O; Chopra T; Munoz-Price LS; Carmeli Y; Kaye KS
Antimicrob Agents Chemother; 2012 Apr; 56(4):2173-7. PubMed ID: 22290982
[TBL] [Abstract][Full Text] [Related]
20. Risk associated with a systematic search of extended-spectrum β-lactamase-producing Enterobacteriaceae.
Prinapori R; Guinaud J; Khalil A; Lecuyer H; Gendrel D; Lortholary O; Nassif X; Viscoli C; Zahar JR
Am J Infect Control; 2013 Mar; 41(3):259-60. PubMed ID: 23062579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
